All In Biotech

Drug Trial Radar · NCT03980483

Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate

A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study Comparing GSK3196165 With Placebo and With Tofacitinib, in Combination With Methotrexate in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate

Last checked: Nov 20, 2026Latest source record: Mar 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,537 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,537

Actual

Start

May 16, 2019

Primary completion

Sep 15, 2021

Study completion Aug 16, 2022

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
Collaborators
IQVIA Pty Ltd
First posted
Jun 10, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study \[contRAst 1 (201790: NCT03980483)\] is a phase 3, randomized, multicenter, double blind study to assess the safety and efficacy of GSK3196165, in combination with methotrexate (MTX), for the treatment of adult participants with moderate to severe active rheumatoid arthritis (RA) who have had an inadequate response to MTX. The study will consist of a screening phase of up to 6 weeks followed by a 52-week treatment phase in which participants will be randomized in a ratio of 6:6:3:1:1:1 to receive GSK3196165 150 milligrams (mg) subcutaneous (SC) weekly, GSK3196165 90 mg SC weekly, tofacitinib capsules (cap) 5 mg twice a day or placebo (three arms, each placebo arm will have 12 weeks placebo followed by 40 weeks active treatment) respectively, all in combination with MTX. Participants who, in investigator's judgement will benefit from extended treatment with GSK3196165, may be included in the long-term extension study \[contRAst X (209564: NCT04333147)\]. For those participants who do not continue into the long term-extension study, there will be an 8 week safety follow-up visit following the treatment phase.

Conditions

  • Arthritis, Rheumatoid

Interventions

  • GSK3196165 (Otilimab)Biological

    GSK3196165 solution in vial/pre-filled syringe (PFS) to be administered SC.

  • Tofacitinib 5 mgDrug

    Tofacitinib cap (over encapsulated 5mg tablet) to be administered orally.

  • PlaceboDrug

    Placebo sterile 0.9 percentage (%) weight by volume (w/v) sodium chloride solution in vial/pre-filled syringe (PFS) to be administered SC.

  • PlaceboDrug

    Placebo cap (containing lactose) to be administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving 20 Percentage (%) Improvement in American College of Rheumatology Criteria (ACR20) at Week 12 Superiority Comparison With PlaceboTime frame: Week 12

Locations

76 sites in 10 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Shanghai, China

  • GSK Investigational Site

    Bengbu, Anhui, China

  • GSK Investigational Site

    Pingxiang, Jiangxi, China

  • GSK Investigational Site

    Changchun, Jilin, China

  • GSK Investigational Site

    Chengdu, Sichuan, China

  • GSK Investigational Site

    Baja, Hungary

  • GSK Investigational Site

    Balatonfüred, Hungary

  • GSK Investigational Site

    Budapest, Hungary

  • GSK Investigational Site

    Budapest, Hungary

  • GSK Investigational Site

    Budapest, Hungary

  • GSK Investigational Site

    Kistarcsa, Hungary

  • GSK Investigational Site

    Székesfehérvár, Hungary

  • GSK Investigational Site

    Szentes, Hungary

  • GSK Investigational Site

    Veszprém, Hungary

  • GSK Investigational Site

    Ahmedabad, India

  • GSK Investigational Site

    Ahmedabad, India

  • GSK Investigational Site

    Ahmedabad, India

  • GSK Investigational Site

    Ahmedabad, India

  • GSK Investigational Site

    Banglore, India

  • GSK Investigational Site

    Belagavi, India

  • GSK Investigational Site

    Hubli, India

  • GSK Investigational Site

    Hyderabad, India

  • GSK Investigational Site

    Jaipur, India

  • GSK Investigational Site

    Jaipur, India

  • GSK Investigational Site

    Kolkata, India

  • GSK Investigational Site

    Nagpur, India

  • GSK Investigational Site

    Nagpur, India

  • GSK Investigational Site

    Nashik, India

  • GSK Investigational Site

    Nashik, India

  • GSK Investigational Site

    New Delhi, India

  • GSK Investigational Site

    Pimpri-Chinchwad, India

  • GSK Investigational Site

    Pune, India

  • GSK Investigational Site

    Pune, India

  • GSK Investigational Site

    Rajkot, India

  • GSK Investigational Site

    Surat, India

  • GSK Investigational Site

    Vadodara, India

  • GSK Investigational Site

    Verona, Veneto, Italy

  • GSK Investigational Site

    Klang, Malaysia

  • GSK Investigational Site

    Kuala Lumpur, Malaysia

  • GSK Investigational Site

    Seremban, Negeri Sembilan, Malaysia

Showing 40 of 76 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.